1054 / 1068
Pembrolizumab a humanized
monoclonal antibody against PD-1
25 heavily pretreated patients with PD-L1-positive
advanced SCCA
Overall response rate of 5/25 (20%)
Stable disease in a further 10/25 patients (40%)
(Ott P et al. Preliminary safety and efficacy results
from KEYNOTE-028 ESMO 2015).